Respiratory Drugs Market Research Report Information By Drug Class (Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs, and Others), By Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, and Others), By Route of Administration (Inhalation, Enteral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (Nort

Global Respiratory Drugs Market Overview

Respiratory Drugs Market Size was valued at USD 15.3 Billion in 2022 and is projected to grow from USD 16.3 Billion in 2023 to USD 26.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.30% during the forecast period (2023 - 2032). Growing demand for pulmonary drug administration, advancements in technology, such as digital/smart inhalers, and an increase in the prevalence of respiratory disorders like COPD, asthma, and cystic fibrosis are all contributing factors, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Respiratory Drugs Market Trends

• Need for sustainable and safe respiratory drugs is driving the market growth

The demand for safe and sustainable respiratory medications is one of the main drivers boosting the global market for these medications. The main cause of death worldwide is respiratory disease, with COPD ranking third in Western Europe and fourth worldwide. Despite the availability of efficient treatments, many patients experience poor quality of life and poorly controlled respiratory disorders. A few new kinds of pharmacological therapy have been established in the last 40 years for the treatment of respiratory illnesses. Leukotriene receptor antagonists are a novel class of medications, although they are insufficiently successful in reducing asthma symptoms. Overall, the need for new drugs in respiratory medicine is a critical issue that will spur market expansion during the projection period.

The need for novel medications to treat respiratory disorders is projected to increase due to common respiratory infections, greater exposure to indoor and outdoor air pollution and toxins from occupational dust, and a rising smoking population worldwide. During the forecast period, the market for respiratory drugs is expected to grow due to the presence of potent new drugs. Increased R&D spending by major key players and growing consumer acceptance of novel medications for the treatment of various respiratory illnesses are expected to fuel the expansion of the respiratory medicines market over the forecast period. Additionally, it is anticipated that during the forecast period, the demand for drugs to treat respiratory diseases will increase along with the patient population.

The growing elderly population and the prevalence of lung disorders are two factors contributing to the market's expansion. The airways and other areas of the lungs are continuously affected by pulmonary illnesses. In primary health care facilities, one of the most common reasons for doctor and physician consultations is respiratory symptoms. Asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (mostly multi-drug resistant tuberculosis) are some of the major chronic respiratory diseases that can be prevented. The Asthma and Allergy Foundation of America reported in March 2021 that around 1 in 13 Americans, or about 25 million people, have asthma. Thus, driving the Respiratory Drugs market revenue.

Respiratory Drugs Market Segment Insights

Respiratory Drugs: Drug Class Insights

The Market segments of Respiratory Drugs, based on Drug Class, includes short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), inhaled corticosteroids (ICS), anticholinergics, antihistamines, vasodilators, combination drugs, and others. The inhaled corticosteroids (ICS) inhaled corticosteroids (ICS) category held the largest share in the market. This can be linked to the fact that they are more effective than other medications and are inexpensive.

Respiratory Drugs Disease Type Insights

The Respiratory Drugs Market segmentation, based on Disease Type, includes asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), pleural effusion, and others. Due to the advantageous reimbursement policies for the treatment of chronic obstructive pulmonary disease (COPD) and the high incidence and mortality of this disease, the chronic obstructive pulmonary disease (COPD) segment is anticipated to have the highest increase.

Respiratory Drugs Route of Administration Insights

The Market segmentation of Respiratory Drugs, based on Route of Administration, includes inhalation, enteral, and parenteral. Due to rising patient demand for inhalers and similarly administered respiratory medications, the inhalation sub-segment held a dominant position on the global market in 2022 and captured the biggest market share.

Respiratory Drugs Distribution Channel Insights

The Market segmentation of Respiratory Drugs segmentation, based on Distribution Channel, includes Hospital pharmacies, retail pharmacies, and online pharmacies. The sub-segment of retail pharmacies dominated the global market in 2022 and is anticipated to continue doing so for the duration of the projection. This is because retail pharmacies offer a variety of medications all at one location.

Figure 1: Respiratory Drugs Market, by Distribution Channel, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Respiratory Drugs Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Respiratory Drugs market dominated the Market of Respiratory Drugs in 2022 and accounted for largest market share. The primary factor anticipated to propel the market's overall expansion over the forecast period is the rising prevalence of respiratory disorders. Additionally, due to the decline in the unemployment rate, the region's per capita health expenditure is on the rise and is anticipated to do so over the course of the forecast period. Due to a rising smoking prevalence and an aging population, COPD cases are projected to rise in the United States. Further, the U.S. Market of Respiratory Drugs held the largest market share, and the Canada Market of Respiratory Drugs was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: RESPIRATORY DRUGS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The European Respiratory Drugs market is expected to witness a decent growth rate during the forecast period. The overall revenue is rising as a result of the increase in projects launched by governmental and non-governmental organizations. Such measures are expected to raise asthma awareness, which will increase the use of medications to treat asthma and cause verticle growth. Further, the German Market of Respiratory Drugs held the largest market share, and the U.K Market of Respiratory Drugs was the fastest growing market in the European region.

Asia Pacific Respiratory Drugs market is projected to exhibit the fastest growth over the forecast period. The discovery of innovative medicines is being accelerated by rising R&D activity, the local presence of major pharmaceutical businesses, and sophisticated healthcare infrastructure. Further, China’s Market of Respiratory Drugs held the largest market share, and the Indian Market of Respiratory Drugs was the fastest growing market in the Asia-Pacific region.

Respiratory Drugs Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their Product lines, which will help the market of Respiratory Drugs, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Respiratory Drugs Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Respiratory Drugs Industry to benefit clients and increase the market sector. In recent years, the Respiratory Drugs Industry has offered some of the most significant advantages to medicine. Major players in the Respiratory Drugs market, including VAPOTHERM, AptarGroup, Inc., Drägerwerk AG & CO., Allied Healthcare, Cardinal Health, NSPIRE HEALTH INC. oninklijke Philips N.V., and others, are attempting to increase market demand by investing in research and development operations.

A medical device firm called Niox Group Plc (Niox Group), formerly known as Circassia Group Plc (Circassia), creates and produces medications for the treatment of respiratory conditions like asthma. The company markets medications including Niox, which is used to treat asthma. Through its network of partners, the company provides its products to asthma specialists in the US, the UK, Sweden, Germany, China, and other nations. The Niox Group is based in Oxford, England, in the United Kingdom. Circassia in March 2019. Obstructive pulmonary disease (COPD) maintenance and treatment with Tudoorza has been given FDA approval.

Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical business that specializes in creating respiratory medications and discovers, creates, and markets organ-selective medications for the treatment of immune system and inflammatory illnesses. Asthma, neurogenic orthostatic hypotension (nOH), gastrointestinal motility disorders, ulcerative colitis, heart failure, chronic kidney disease (CKD), gastroparesis, and concurrent bacteremia are among the conditions the company is looking at with its pipeline candidates. Theravance Biopharma has contracts with other pharmaceutical firms and owns financial stakes in prospective future payments from Glaxo Group Limited or one of its affiliates to Innoviva, Inc. The US, Ireland, and the UK all have subsidiaries for the business. San Francisco, California, in the United States, serves as the headquarters for Theravance Biopharma. A new drug application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of people with chronic obstructive pulmonary disease (COPD) was approved by the FDA in November 2018 by Theravance Biopharma and Mylan N.V.

Key Companies in the Respiratory Drugs market include

• AptarGroup, Inc.


• Drägerwerk AG & CO.


• Allied Healthcare


• Cardinal Health


• NSPIRE HEALTH INC.


• VAPOTHERM


• Koninklijke Philips N.V.


• others

Respiratory Drugs Industry Developments

April 2022 A novel type of cell that is found deep inside the human lung and may be crucial in lung illnesses has been identified by Penn Medicine. To find the novel cells, which they named respiratory airway secretory cells (RASCs), the researchers examined human lung tissue.

December 2021 In its drug development pipeline, AstraZeneca has a novel target for idiopathic pulmonary fibrosis (IPF) that was discovered using BenevolentAI's technology. Notably, this is the second novel target from the collaboration that has been acknowledged, accepted, and added to AstraZeneca's pipeline. The current focus of BenevolentAI's partnership with AstraZeneca is the identification of potential innovative medicines for IPF and chronic kidney disease (CKD).

Respiratory Drugs Market Segmentation

Respiratory Drugs: Drug Class Outlook

• Short-Acting Beta2-Agonists (SABA)


• Long-Acting Beta2-Agonists (LABA)


• Inhaled Corticosteroids (ICS)


• Anticholinergics


• Antihistamines


• Vasodilators


• Combination Drugs


• Others

Respiratory Drugs Disease Type Outlook

• Asthma


• Chronic Bronchitis


• Chronic Obstructive Pulmonary Disease (COPD)


• Pleural Effusion


• Others

Respiratory Drugs Route of Administration Outlook

• Inhalation


• Enteral


• Parenteral

Respiratory Drugs Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies

Respiratory Drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America